耐性克服とＤＤＳ　　Ｃｅｌｌ　ｄｅｌｉｖｅｒｙ　ｓｙｓｔｅｍに基づく次世代がん免疫療法

• 杉田 敏樹

  大阪大学大学院薬学研究科薬剤学分野

• 高 建青

  大阪大学大学院薬学研究科薬剤学分野

• 中川 晋作

  大阪大学大学院薬学研究科薬剤学分野

書誌事項

タイトル別名

• Development of cell delivery system for optimal cancer immunotherapy
• Development of cell delivery system for optimal cancer immunotherapy
• Cell delivery systemに基づく次世代がん免疫療法

抄録

The immune cells such as cytotoxic T lymphocytes, NK cells, and antigen presenting cells play a central role in cancer immunotherapy. These effector cells can be used as “drugs” for cancer therapy from the view of drug delivery system (DDS). We anticipated that optimal cancer immunotherapy can be achieved by controlling of the distribution of these so-called “live drugs” in the body. In the present study, we focus on a cell delivery system which can potentially control the systemic pharmacokinetics of immune cells and especially focus on the cell migrating molecule, chemokine and its receptor, as well as its use in cancer immunotherapy.

収録刊行物

• Ｄｒｕｇ　Ｄｅｌｉｖｅｒｙ　Ｓｙｓｔｅｍ

  Ｄｒｕｇ　Ｄｅｌｉｖｅｒｙ　Ｓｙｓｔｅｍ 20 (1), 42-48, 2005

  日本DDS学会

キーワード

• drug delivery system
• cell delivery system
• chemokine
• chemokine receptor
• cancer immunotherapy

詳細情報

• CRID: 1390001204641687936
• NII論文ID: 10014282827
• NII書誌ID: AN10084591
• DOI: 10.2745/dds.20.42
• ISSN: 18812732
• ISSN: 09135006
• Web Site: https://search.jamas.or.jp/link/ui/2005095500
• 本文言語コード: ja
• データソース種別:
  • JaLC
  • Crossref
  • CiNii Articles
• 抄録ライセンスフラグ: 使用不可